Minutes of the 2022 Annual General Meeting of Shareholders

of

Winnergy Medical Public Company Limited

Date, time, and place

The 2022 Annual General Meeting of Shareholders of Winnergy Medical Public Company Limited (the "**Company**") was convened on 22nd April 2022, at 09:00 hrs., by electronic meeting at Conference Room, 4th Floor, 634/4, Soi Rankhamhaeng 39 (Thepleela 1), Pracha Uthit Road, Wang Thonglang, Wang Thonglang, Krung Thep Maha Nakhon, 10310.

Directors in attendance to this meeting

1.	Asst. Prof. Dr. Terdsak Rojsurakitti	Chairman of the Board
2.	Mrs. Kwantieda Wattanaworakijkul	Independent Director / Chairman of the Audit Committee / Nomination and Remuneration Committee
3.	Mr. Phisut Areemitra	Independent Director / Chairman of the Nomination and Remuneration Committee / Audit Committee
4.	Mrs. Renu Ubol (M.D.)	Independent Director / Audit Committee
5.	Mr. Nanthiya Darakananda	Director / Chairman of the Risk Management Committee / Chairman of the Executive Committee / Nomination and Remuneration Committee / Chief Executive Officer
6.	Mr. Amarin Pataranavig	Director
7.	Mr. Tanakorn Vidhayasirinun	Director
8.	Ms. Jinhatha Panyasorn (D.D.S)	Director
9.	Mr. Boontalerng Khampuanboot	Director / Risk Management Committee / Executive Director / Chief Executive Officer of Sales and Marketing - Blood Bank Diagnostic Products
10.	Ms. Yodjuta Kunjara na Ayudhya	Director / Executive Director / Chief Executive Officer of Operation / Company Secretary

Executive in attendance to this meeting

1.	Mr. Rachan Arayawongchai	Risk Management Committee / Chief Financial Officer / Executive Director

Legal Advisors in attendance from MSC International Law Office Co., Ltd

1. Mrs. Sawita Suwansawat — Founder & CEO
2. Mr. Sirikorn Pakkahn — Associate
3. Mr. Thanasin Limthammarot — Associate

Auditors in attendance from ANS Audit Co., Ltd.

1. Ms. Atchara Suknaibaiboon — Certified Public Accountant License No. 4642

The Meeting start at 09.00 hrs.

Mr. Pattawut Thamuang, Investor Relation Manager, served as the Meeting Facilitator (the "**Facilitator**") gave a welcome speech to the shareholders and attendees who attended the 2022 Annual General Meeting of Shareholders (the "**Meeting**") through Electronic Meeting System.

The Facilitator informed the Shareholders' Meeting that there were 3 shareholders attending the Meeting, each holding 100,101 shares, and 37 shareholders attending via proxies, each holding 287,180,510 shares. In total, 40 shareholders and proxies attended the Meeting, holding a total of 287,280,611 shares, or 71.8202 percent of the Company's total issued shares.. The quorum was thus constituted in accordance with Section 33 of the Company's Articles of Association, which states that a quorum at a shareholder meeting must consist of at least twenty-five (25) shareholders and proxies (if any), and shareholders must own at least one-third (1/3) of the total number of shares sold by the Company, or 133,333,334 shares.

The Facilitator invited Asst. Prof. Dr. Terdsak Rojsurakitti, Chairman of the Board to serve as the Chairman of the Meeting (the "**Chairman**").

The Chairman gave a welcome speech to the shareholders and participants who attended the Company's meeting, informing them that the meeting was held using the Electronic Meeting System in accordance with the EMERGENCY DECREE ON ELECTRONIC MEETINGS, B.E. 2563, due to the situation of the Coronavirus-19 in Thailand ("**COVID-19**") spreading throughout Thailand. The Company provided for the directors, executives, and team members who attended the Meeting to function in line with sanitary requirements and the Coronavirus Disease Epidemic Administrative Center 2019 standard in the Company's meeting room (Sor Bor Kor.)

The Company has appointed Digital Access Platform Co., Ltd., or DAP, a company in the Stock Exchange of Thailand group, to conduct the Meeting through the Electronic Meeting System in attendance, question submission, and vote in order to advance the Meeting using the Electronic Meeting System.

The Facilitator introduced the directors, the executive, and the advisors of the Company, and in order to ensure that the Meeting was conducted in accordance with good corporate governance principles with respect to voting, the Facilitator informed the Meeting on the following procedures for casting and counting of votes:

1. Asking or expressing opinions

1) Shareholders can submit questions or comments in the Electronic Meeting System during the Meeting. The Company gives an opportunity to shareholders to inquire through the Meeting System by pressing the button to turn on the microphone but for smoothness and convenience of shareholders. The Meeting Facilitator will read the questions sent by the shareholders into the system on behalf of the shareholders.

2) The Company will take the questions in advance. Or during today's meeting to answer only on matters related to the Meeting agenda for other questions that were not answered at the Meeting, the Company will continue to answer and publish them on the Company's website.

2. Vote counting methods for each agenda

The Meeting is an electronic meeting. Therefore, no ballots were printed. Before voting on each agenda, will inform the attendees about the resolution and vote counting for each agenda. After the shareholders and proxies have known the details of each agenda. The shareholders and proxies are requested to perform the voting procedures as follows:

2.1 Each shareholder is entitled to one vote per share.

2.2 When the shareholders are asked to vote on each agenda item, the system will allow the shareholders to do so through Electronic Meeting system. (Electronic Meeting)

2.3 Shareholders or proxies are required to vote only for only one option: "Agree", "Disagree" or "Abstain". Partial voting is not conceivable. If the shareholders do not use their right to vote, the system will assume that the shareholders voted "Agree" on that agenda item.

2.4 In the event of a tie on any agenda, the casting vote will be applied.

2.5 The Company will inform the Meeting on every agenda of the vote counting results. Because some shareholders may attend the Meeting during the Meeting, the number of shareholders in each agenda may not be equal before that agenda is completed. To ensure that the vote-counting in the Shareholders' Meeting is accurate and transparent, in accordance with the Company's Articles of Association.

2.6 If the law or the Company's Articles of Association provide otherwise, the Meeting's resolution will be in line with that legislation or regulation, and the Meeting will be informed before voting on each agenda item.

2.7 The votes of those proxies who attended the Meeting and had already voted in the Company's proxy had already been tabulated and would be combined with the votes cast by shareholders via the E-Voting System.

The Chairman proposed to the Shareholders' Meeting to consider the agenda items as follows:

Agenda No. 1 Matters to be informed.

The Chairman informed the Meeting that the 2022 Annual General Meeting of Shareholders is the first general meeting of shareholders. After the Company was converted the Company to a public company limited on 2nd September 2020 and was listed on the Stock Exchange of Thailand (SET) on 11th May 2021 and There are no questions from shareholders prepared for today's meeting..

The Chairman gave the Meeting an opportunity to request for further information and ask whether there are any questions sent by shareholders in advance.

There were no shareholders or proxies who raised any questions on this Agenda.

This agenda was for shareholders' acknowledgment; voting is not required.

Agenda No. 2 To consider and adopt the Minutes of the 2021 Annual General Meeting Shareholders, held on 23rd April 2021.

The Chairman informed the Meeting that according to the 2021 Annual General Meeting of Shareholders was held on 23rd April 2021 and the Minutes of the 2021 Annual General Meeting of Shareholders has already been submitted to the Ministry of Commerce within the period as required by law.

The Board has recommended that the Minutes of the 2021 Annual General Meeting of Shareholders , held on 23rd April 2021, be adopted because they were accurately recorded.

The Chairman gave the Meeting an opportunity to request for further information and ask whether there are any questions sent by shareholders in advance.

There were no shareholders or proxies who raised any questions on this Agenda.

Then, the Chairman proposed the Meeting to consider and certify the minutes of the 2021 Annual General Meeting of Shareholders, held on 23rd April 2021.

To approve this matter, a resolution must be passed by a majority vote of the shareholders who attend the Meeting and cast their votes.

Meeting Resolution

The Meeting considered and resolved to adopt the Minutes of the2021 Annual General Meeting of Shareholders, held on 23rd April 2021 with details as proposed, with the following votes:

Result	Number of votes (1 share = 1 vote)	Percentage of shareholders attending the Meeting and casting their votes
Agree	292,121,211	100.0000
Disagree	0	0.0000
Abstained	0	-
Voided ballots	0	-
Total	**292,121,211**	**100.0000**

Agenda No. 3 To acknowledgment the Board of Directors' report on the Company's operating results for the year 2021

The Chairman assigned Mr. Rachan Arayawongchai, Chief Financial Officer ("**Chief Financial Officer**") to explain the details of this agenda to the Meeting.

Chief Financial Officer explained to the Meeting as follows:

In terms of key performance reports and an overview of operating results for the past three years, the Company had revenue in 2019 of Baht 492.38 million, revenue in 2020 of Baht 530.53 million, and revenue in 2021 of Baht 538.69 million, which increase Baht 8.16 million compared to the year 2020, although the Company encountered the epidemic situation of COVID-19, which has affected revenues during the past two years, the Company still has a good income growth. Meanwhile, the Company's gross profit margin ranges between 45 and 48 percent. The Company's gross profit margin has fallen slightly from around 1.62 percent in 2020 to about 1.62 percent in 2021. Over the last three years, the Company's net profit has steadily increased. The Company's net profit in 2021 increased by Baht 13.62 million over the previous year.

Revenues for women's health care have increased as a result of the Company's efforts. The majority of the revenues come from National Health Security Office projects that promote cervical cancer screening. The revenue from this project in 2021 was Baht 52.12 million, or 29.13 percent, resulting in a higher total revenue for the Company in 2021 than the previous year. Despite the fact that COVID-19 is on the rise. As a result, the proportion of revenue generated by other parts decreases.

Blood banking and blood safety group revenue has decreased as a result of the COVID-19 epidemic, which has resulted in fewer hospital visits and blood donations. As a result, revenue in 2021 will be Baht 9.57 million lower than in 2020.

Revenue from Cell Therapy Technology and Immunotherapy Group has decreased from 2019 to 2021, owing to the Company's sale of high-value stem cell sorting machines to Chulalongkorn Hospital in 2019, but the Company has been affected by the COVID-19 epidemic, resulting in the closure of laboratories for treating patients in 2020 and 2021. As a result, consumption of this category of products has dropped significantly.

In 2019, before the Covid-19 situation, revenue from other product groups came from the sale of mosquito and blood-sucking insect trap products that the subsidiary sold through the retail business and various department stores. However, when the Covid-19 epidemic occurs, resulting in a lockdown measure that affected sales of products in this group because it was the primary channel for distributing products, the Company has added more distribution channels through online channels in 2022, which was expected to increase revenue from this group of products.

For an overview of income, costs, and gross profit, the Company's overall gross profit from 2019 to 2021 was approximately 45 percent to 48 percent of revenue, due to the proportion of sales of various product groups and increased depreciation rate from medical device investments in the previous year. The Company's gross profit margin in 2021 was 1.45 percent lower than in 2020 due to distribution costs, which included sales and promotional expenses. From 2019 to 2021, the overall cost of distribution and administrative expenses was approximately 35 percent of total revenue, and in 2021, it was Baht 8.38 million, which was higher than the year 2020 due to an increase in personnel expenses following the annual salary adjustment cycle, as well as an increase in works according to the investment plan and the expansion of the project, including the cost of listing on the stock exchange, of which the expenses were Baht 5.82 million.

The Company has continued to increase its net profit since 2019, with the net profit of 2021 exceeding the net profit of 2020 by Baht 13.61 million , or approximately 26.3 percent, compared to the previous year which showed a net profit margin of 12.10 percent of total revenue. Income, costs, and expenses all contributed to it.

The Company plans to expand its business in 2022, whether it was the outbreak of COVID-19, which continued to be violent, causing the government to issue control measures to limit the number

of people who had health check-ups, and the number of blood donors decreased due to a decrease in blood demand, as well as the number of Medical Tourists. Laboratories and research projects have been unable to operate, negatively impacting the Company's performance during the last year. The management team was aware of the problem.. In order to continue to grow, new products and services are constantly being recruited to meet changing needs, including maintaining relationships with customers and customers in order to generate profits, as well as appropriate risk management to accommodate the volatility of various environmental factors..

For an overview of the past 3 years of operating results, it could be seen that from 2019 to 2021that the Company's operating results had grown from Baht 492 million to Baht 538 million in 2021. The Company expects that in 2022, the revenue of the Company will grow to Baht 835 million, or having a growth of more than 55 percent.

With regard to the revenue growth structure from 2021 to 2022, the Company forecasts that the Company will have revenue growth of Baht 297 million or 55 percent, of which 73 percent come from the existing product portfolios and planned investment projects, and 27 percent from new products.

In the first quarter of 2022, the Company will launch EMONO Therapy, COVID-19 products and RT-PCR testing labs. In the second quarter of 2022, the Company will launch both online and offline ATK test suites, ae well as the Mobile Blood project. In the third quarter, the Company will launch HPV-related products and HIV testing equipment.The Company will launch protective clothing for blood-sucking insects and mosquitoes, as well as EMONO therapy in the fourth quarter of 2022.

The Board has agreed to requests the Meeting to acknowledge the report on the Company's operating results for the year 2021, ended 31st December 2021 along with the significant changes that occurred during the year that occurred provided in the Form 56-1 One Report for 2021 (Annual Report), as shown in Enclosure 2.

The Chairman gave the Meeting an opportunity to request for further information and ask whether there are any questions sent by shareholders in advance.

There were no shareholders or proxies who raised any questions on this Agenda.

This agenda was for acknowledgment. Therefore, there was no voting.

<u>Agenda No. 4</u> To consider and approve Financial Statements of the Company for the year 2021, ended 31st December 2021 which have been audited by the certified auditor, and acknowledge the certified public accountant's report.

The Chairman informed the Meeting that according to the Public Limited Companies Act, B.E.2535, the Company must prepare the balance sheets and statements of income at the end of fiscal year, which have been audited by an external auditor, and submit these to the shareholders' meeting for approval.

The Chairman assigned Chief Financial Officer to report the details of this agenda to the Meeting.

The Chief Financial Officer reported the Meeting the information which can be summarized as follows:

List	Consolidated financial statements		Company financial statements	
	2021	2020	2021	2020
Total assets	755.46	492.10	747.69	479.96
Total liabilities	183.46	303.31	170.41	288.03
Total revenue	538.69	530.53	520.93	511.51
Net profit (loss) (Shareholders' equity)	65.20	51.89	67.35	49.45
Earnings (loss) per shares (Baht/share)	0.18	0.32	0.19	0.30

Total assets at the end of 2021 were Baht 755.46 million, increasing from the end of 2020 by Baht 263.36 million or 53.51 percent with current assets accounting for 55 percent of total assets and non-current assets accounting for 45 percent of current assets.

Liabilities at the end of 2021 were 129.12 million Baht, decreasing from the end of 2020 by Baht 107.83 million or 45.51 percent, while non-current liabilities decreased by Baht 12.03 million or 18.12 percent, resulting in the decrease of total liabilities from Baht 303.31 million at the end of 2020 to Baht 183.47 million at the end of 2021, due to repayment of bank overdrafts and short-term loans from financial institutions, including repayment of long-term loans from financial institutions.

At the end of 2021, the Company had shareholders' equity of Baht 571.99 million, increase Baht 383.20 million or 202.98 percent from the end of 2020 due to the initial public offering of shares which is 90,000,000 newly issued ordinary shares with a par value of Baht 0.50 per share at a purchase price of Baht 3.10 per share, resulting in a total share premium of Baht 299.69 million and an additional Baht 60 million in paid-up capital and dividend payment from retained earnings of Baht 41 million and net profit for the 12-month period of 2021 totaling Baht 65.20 million, resulting in higher shareholders' equity from the previous year.

For the statement of comprehensive income in 2021, the Company had revenues of Baht 538.70 million, costs of Baht 295.37 million, gross profit of Baht 243.33 million, profit for the year 2021 amounted to Baht 65.24 million.

The Chairman assigned Mrs. Kwanthida Wattanaworakitkul, Chairman of the Audit Committee ("**Chairman of the Audit Committee**") to clarify the opinion of the Audit Committee to the Meeting.

The Chairman of the Audit Committee provided that the Audit Committee has reviewed the Company's financial statements for the year ended 31st December 2021, which have been audited and signed by Mr. Atipong Atopongsakul a certified public accountant license no. 3500 of ANS Audit Company Limited and recommended that the Board of Directors shall submit the Company's financial statements for the year ended 31st December 2021 to the shareholders' meeting for approval.

The Chairman informed the Meeting that the Board has agreed to present the Company's audited financial statements for the year ended 31st December 2021, as duly audited and certified by the auditor from ANS Audit Co., Ltd.

The Chairman gave the Meeting an opportunity to request for further information and ask whether there are any questions sent by shareholders in advance.

There were no shareholders or proxies who raised any questions on this Agenda.

The Chairman proposed to the Meeting to consider and approve the Company's financial statements for the year 2021 ending on 31st December 2021 which have been audited by the auditor. and acknowledge the report of the certified public accountant.

To approve this matter, a resolution must be passed by a majority vote of the shareholders who attend the Meeting and cast their votes.

Meeting Resolution

The Meeting considered and resolved to approve the Financial Statements of the Company for the year 2021, ended 31st December 2021 which have been audited by the certified auditor, and acknowledge the certified public accountant's report with details as proposed with the following votes:

Result	Number of votes (1 share = 1 vote)	Percentage of shareholders attending the Meeting and casting their votes
Agree	292,121,211	100.0000
Disagree	0	0.0000
Abstained	0	-
Voided ballots	0	-
Total	**292,121,211**	**100.0000**

Agenda No. 5 To consider and approve the allocation of the net profit for the year 2021 as legal reserve.

The Chairman informed the Meeting that in 2021, the Company had a net profit from operations of Baht 67,356,171.14, which according to the Public Company Limited Act Section 116 and Article 45 of the Company's Articles of Association, the Company must allocate part of the annual net profit as a reserve of not less than 5 percent of the annual net profit less the accumulated loss brought forward (if any) until this reserve is not less than 10 percent of the registered capital.

At the end of 2020, the Company has legal reserves of 6,858,311.54 Baht, of which the Company still has reserved funds that are insufficient to meet legal requirement. Therefore, the Company must allocate a portion of the net profit for the year 2021 as a reserve of not less than 5 percent of the annual net profit of Baht 3,367,808.56, of which the Company will have a total legal reserve of Baht 10,226,120.10 or equivalent to 5.11 percent of the Company's registered capital which still has to reserve additional legal reserves to complete as required by law in the amount of Baht 9,773,879.90.

The Board of Directors considered it appropriate to propose to the Annual General Meeting of Shareholders for the year 2022 to consider and approve the allocation of the net profit from the Company's operating results as legal reserves of not less than 5 percent of the annual profits, less the accumulated losses brought forward (separate financial statements) at Baht 3,367,808.56; the Company shall have a legal reserve by law at Baht 10,226,120.10 or equivalent to 5.11 percent of the Company's registered capital.

The Chairman gave the Meeting an opportunity to request for further information and ask whether there are any questions sent by shareholders in advance.

There were no shareholders or proxies who raised any questions on this Agenda.

The Chairman then proposed to the Meeting to consider and approve the allocation of net profit as legal reserve amounting to Baht 3,367,808.56 .

To approve this matter, a resolution must be passed by a majority vote of the shareholders who attend the Meeting and cast their votes.

Meeting Resolution

The Meeting considered and resolved to approved the allocation of net profit as legal reserve in the amount of Baht 3,367,808.56 with details as proposed with the following votes:

Result	Number of votes (1 share = 1 vote)	Percentage of shareholders attending the Meeting and casting their votes
Agree	292,121,211	100.0000
Disagree	0	0.0000
Abstained	0	-
Voided ballots	0	-
Total	**292,121,211**	**100.0000**

Agenda No. 6 To consider and approve the dividend payment for the year 2021.

The Chairman informed the Meeting that the Company has established a dividend policy for shareholders at a rate of not less than 40 percent of the net profit remaining after the deduction of all types of reserves according to the law and the Company's policy which is considered by the net profit according to the separate financial statements of the Company. Such dividend payment is subject to change depending on the business plan, financial status, liquidity, business expansion plans, other necessities, and suitability must not affect the normal operations of the Company and the subsidiary Company.

As of 31st December 2021, the Company recorded a net profit in the separate financial statements of Baht 67,356,171.14, and there are no accumulated losses. Therefore, the Company can pay dividend payments to the Shareholders pursuant to Section 115 of the Public Limited Companies Act B.E. 2535 and Article 44 of the Company's Article of Association.

The Chairman has assigned Chief Financial Officer explained the details of this agenda to the Meeting.

Chief Financial Officer explained to the Meeting, can be summarized as follows:

Baht

Net profit from separate financial statements	67,356,171.14
Allocated as legal reserve	3,367,808.56
Net profit after legal reserve	63,988,362.58
Dividend payout value per share (Not less than 40 percent according to the Company's dividend payment policy)	0.065 t
Number of shares	400,000,000 shares
Total dividend payment	26,000,000.00

The Chairman informed the Meeting that the Board of Directors considered appropriate to propose to the 2021 Annual General Meeting of Shareholders to consider and approve the dividend payment for the year 2021 by cash at the rate Baht 0.065 per share, totaling Baht 26,000,000 million.

In this regard, The record date to determine the list of shareholders entitled to receive dividend is scheduled on 18th March 2022, and the dividend payment shall be made on 11th May 2022.

In additional, an individual shareholder shall be deducted 10 percent withholding tax, and shall be entitled to a tax credit equaling the product of dividend times 20/80

The Chairman gave the Meeting an opportunity to request for further information and ask whether there are any questions sent by shareholders in advance.

There were no shareholders or proxies who raised any questions on this Agenda.

The Chairman, therefore, proposed to the Meeting to consider and approve the dividend payment for the year 2021 at the rate of Baht 0.065 per share to the total shareholders of 400 million shares, totaling a dividend of Baht 26,000,000 or 40.63 percent of the net profit of the year 2021. And the remaining net profit will be carried forward as retained earnings.

To approve this matter, a resolution must be passed by a majority vote of the shareholders who attend the Meeting and cast their votes.

Meeting Resolution

The Meeting considered and resolved to approved the dividend payment for the year 2021 with details as proposed with the following votes:

Result	Number of votes (1 share = 1 vote)	Percentage of shareholders attending the Meeting and casting their votes
Agree	292,121,211	100.0000

Disagree	0	0.0000
Abstained	0	-
Voided ballots	0	-
Total	**292,121,211**	**100.0000**

<u>Agenda No. 7</u> To consider and approve the election of Directors to replace those retiring by rotation

The Chairman informed the Meeting that according to the Public Limited Companies Act B.E. 2535 and Clause 17 of the Company's Articles of Association, one-third of all directors must retire by rotation on the date of each Annual General Meeting of the Shareholders. The Director who retire during the first and the second years following the registration of the Company shall be drawn by lots. In every subsequent year, the directors who have been longest in office shall retire. In 2022 Annual General Meeting of the Shareholders which is the second year after the registration as a public company limited, hence, the Company shall be drawn by lots for the directors retiring in this year. The 3 directors listed below are due to retire by rotation in 2022.

1. Mr. Nanthiya Darakananda	Director / Chairman of the Risk Management Committee / Chairman of the Executive Committee / Nomination and Remuneration Committee / Chief Executive Officer
2. Mr. Tanakorn Vidhayasirinun	Director
3. Ms. Yodjuta Kunjara na Ayudhya	Director / Executive Director / Chairman of the Risk Management

In order to comply with the principles of corporate governance and so that shareholders can vote independently The 3 directors who had to retire by rotation, namely Mr. Nanthiya Darakananda, Mr. Tanakorn Vidhayasirinun, and Ms. Yodjuta Kunjara na Ayudhya, left the Meeting room during the consideration of this agenda.

The Board, with the exception of the directors who have conflict of an interest has agreed and recommends that the following retiring directors be re-elected for another term of office at the Annual General Meeting of Shareholders for the year 2022.

The directors proposed for re-appointment meet all the requirements stipulated in the Public Limited Companies Act, B.E. 2535 and relevant regulations of the Capital Market Supervisory Board. However, the Board of Directors agreed that the 3 directors are eligible persons with skill, knowledge, experience, and beneficial to the Company including a good understanding of the Company's businesses. Therefore, they are qualifying as per the criteria of the Board of Directors.

The Board would like to propose to re-elect as director for another term.

However, before voting for the election of directors, the Chairman proposed to the Meeting to determine the method for electing directors by electing the Board of Directors It is in accordance with the Company's Articles of Association Article 16 (2) in the election of directors. Voting methods may be used to select directors individually, one at a time, or several at a time to form a single

committee. According to the total number of directors to be elected at that time, as the shareholders' meeting deems appropriate. This is the electoral method, whether to elect a complete set of 3 directors or to elect individual directors.

The Chairman asked the Meeting whether he or she would like to elect directors by electing several directors at a time to form a single committee. According to the total number of directors to be elected or electing directors individually, one at a time.

Ms. Waraporn Thong-in, a proxy from the shareholder, proposed the election of several directors to be a single committee, according to the total number of directors to be elected.

The Chairman gave the Meeting an opportunity to request for further information and ask whether there are any questions sent by shareholders in advance.

There were no shareholders or proxies who raised any questions on this Agenda.

The Chairman then proposed to the Meeting to consider and approve the election of directors by electing several directors at a time to form a single committee. According to the total number of directors to be elected.

The Meeting has considered passing a resolution to approve the election of directors by electing several directors at a time to form a single committee according to the total number of directors to be elected with the following votes:

Result	Number of votes (1 share = 1 vote)	Percentage of shareholders attending the Meeting and casting their votes
Agree	291,431,311	99.7699
Disagree	671,900	0.2300
Abstained	0	-
Voided ballots	0	-
Total	**292,103,211**	**100.0000**

The Chairman then proposed to the Meeting to consider and approve the election of directors to replace those who retired by rotation. By using the method of electing the 3 directors who must retire by rotation, namely: Mr. Nanthiya Darakananda, Mr. Tanakorn Vidhayasirinun, and Ms. Yodjuta Kunjara na Ayudhya, to be reinstated for another term.

To approve this matter, a resolution must be passed by a majority vote of the shareholders who attend the Meeting and cast their votes.

Meeting Resolution

The Meeting considered and resolved to approve the election of 3 directors to replace those who retired by rotation, namely Mr. Nanthiya Darakananda, Mr. Tanakorn Vidhayasirinun, and Ms. Yodjuta Kunjara na Ayudhya, to resume their positions as the Company's directors for another term with details as proposed with the following votes:

Result	Number of votes (1 share = 1 vote)	Percentage of shareholders attending the Meeting and casting their votes
Agree	291,431,911	99.7699
Disagree	671,800	0.2300
Abstained	0	-
Voided ballots	0	-
Total	**292,103,711**	**100.0000**

Agenda No. 8 To consider and approve the remuneration of the Company's Directors for the year 2022

The Chairman informed the Meeting that according to the Clause 22 of the Company's Articles of Association, the Company's Directors are eligible to receive remuneration in the form of awards, meeting fee, retirement pension, bonuses and other benefits in other forms as per the approval of the Shareholders' Meeting. However, the Directors' remuneration and commensurate with each member's responsibility and performance and review annually, the details are as follows.

Meeting allowance for the Board of Directors and each of the subcommittees

Position	Meeting allowance (Baht/meeting/person)
Board of Directors	
• Chairman of the Board of Directors	30,000
• Directors	15,000
Audit Committee	
• Chairman of the Audit Committee	20,000
• Committee	15,000
Other sub-committees	
• Chairman	15,000
• Committee	10,000

Remark: 1. Other sub-committee means the Nomination and Remuneration Committee, Executive Committee, and Risk Management Committee.

2. The Company has fix the remuneration for the Board by compared with other companies within the same level of business and registered in the Stock Exchange of Thailand. The Remuneration has been already reviews by the Nomination and Remuneration Committee.

3. Directors who are the Company's executives, employees, major shareholder companies or representative from major shareholders shall not receive any remuneration as member of the Board or member of Sub-Committee.

Board of Directors which has been approved by the Nomination and Remuneration Committee. It is deemed appropriate to propose to the 2022 Annual General Meeting of Shareholders to consider and approve the remuneration of the Board of Directors and Sub-Committees for the year 2022 with details as proposed.

The Chairman gave the Meeting an opportunity to request for further information and ask whether there are any questions sent by shareholders in advance.

There were no shareholders or proxies who raised any questions on this Agenda.

The Chairman then proposed to the Meeting to consider and approve the remuneration of the Board of Directors and sub-committees for the year 2022.

To approve this matter, a resolution must be passed by not less than two-thirds of the total number of votes of the shareholders who attend the Meeting.

Meeting Resolution

The Meeting considered and resolved to consider and approve the remuneration of the Company's Directors for the year 2022 with details as proposed with the following votes:

Result	Number of votes (1 share = 1 vote)	Percentage of shareholders attending the Meeting
Agree	292,103,711	100.0000
Disagree	100	0.0000
Abstained	0	0.0000
Voided ballots	0	0.0000
Total	**292,103,811**	**100.0000**

Agenda No. 9 To consider and approve the appointment of the Company's external auditors and fix the audit fees for the year 2022

The Chairman informed the Meeting that According to the Section 120 of the Public Limited Companies Act, B.E. 2535 and Article 36 of the Company's Article of Association, the appointment of the Company's external auditors and the audit fees must be approved at the Annual General Meeting of Shareholders, and the Shareholders' Meeting might be reappointed the auditors continuously.

The Chairman assigned the Chairman of the Audit Committee to clarification of the opinion of the Audit Committee to the Meeting.

The Chairman of the Audit Committee informed the Meeting that The Audit Committee recommended the reappointment of ANS Audit Company Limited as the Company's external audit firm for the Company and its Subsidiaries for the year 2022 due to their audit performance standard, experiences and expertise in auditing as well as good business understanding. When compared to the scope of services offered, workload and the audit fee rate of other external auditors. This will be ANS's five-year term (fiscal years 2022). In addition, ANS and the proposed auditors are independent and have no conflict of interest with the Company, the management, the major shareholders or any related person.

The Chairman informed the Meeting that The Board of Directors agrees with the proposal of the Audit Committee to propose to the 2022 Annual General Meeting of Shareholders for approval appointment the auditors and determine the audit fee for the year 2022 with details as follows:

Consider appointing an auditor from ANS Audit Co., Ltd. to be the Company's auditor for the year 2022, whose names are as follows:

1.	Mr. Atipong Atipongsakul	Certified Public Accountant No. 3500; and/or
2.	Mr. Vichai Ruchitanont	Certified Public Accountant No. 4054; and/or
3.	Mr. Sathien Vongsnan	Certified Public Accountant No. 3495; and/or
4.	Ms. Kultida Pasurakul	Certified Public Accountant No. 5946; and/or
5.	Mr. Yuttapong Chuamuangpan	Certified Public Accountant No. 9445; and/or
6.	Ms. Atchara Suknaibaiboon	Certified Public Accountant No. 4642.

Any of the above auditor can conduct the audit and express an opinion on the Company's financial statements and its subsidiaries. In case of the aforementioned auditors unable to perform their duties, ANS audit company limited shall provide other auditors of its company to perform as an external auditor instead. And the Company's audit fees for the year 2022 were Baht 1,720,000 and for its subsidiaries were Baht 400,000, totaling Baht 2,120,000, excluding other actual payable non-audit fees.

The Chairman gave the Meeting an opportunity to request for further information and ask whether there are any questions sent by shareholders in advance.

There were no shareholders or proxies who raised any questions on this Agenda.

The Chairman then proposed to the Meeting to consider and approve the appointment of auditors and fix the auditor's remuneration for the year 2022.

To approve this matter, a resolution must be passed by a majority vote of the shareholders who attend the Meeting and cast their votes.

Meeting Resolution

The Meeting considered and resolved to approve the appointment of the Company's external auditors and fix the audit fees for the year 2022, with details as proposed with the following votes:

Result	Number of votes (1 share = 1 vote)	Percentage of shareholders attending the Meeting and casting their votes
Agree	292,103,211	99.9998
Disagree	500	0.0002
Abstained	0	-
Voided ballots	0	-
Total	**292,103,711**	**100.0000**

<u>Agenda No.10</u> Other matters (if any)

The Chairman asked the Meeting, if any shareholders or proxies wished to ask questions or express opinions. or have additional questions sent by the shareholders in advance in this other agenda?

Shareholders or proxies Questions or comments on this agenda are as follows:

Mr. Nuttawadee Pikulwong asked that due to the war in foreign countries, whether it will affect the Company or not and how?

Mr. Nanthiya Darakananda, Chief Executive Officer ("**Chief Executive Officer**") explained that the current war situation directly affects the Company, because the Company is an importer of products directly from abroad. The first effect is that delivery periods were extended due to the need to avoid war-torn transport routes, resulting in greater costs and longer lead times.. However, the Company has taken corrective action by increasing the hoarding of products because the Company's products are products that customers use regularly. Therefore, it can be assured that additional hoarded goods can be sold. The second is the significant increase in the exchange rate over the past 4 months. As a result, for each transaction the Company purchases, the Company enters into forwarding foreign currency contracts with banks. Furthermore, in the product area, where the price of the product can be adjusted, the Company has increased as necessary. However, a customer with a long-term contract with that company cannot be adjusted until the contract time expires, and the company has also saved in other areas, such as marketing expenses. However, management feels that these challenges may be efficiently handled as the Company grows..

Mr. Anujit Ayusanin, a proxy from the Thai Investors Association, asked what would be the Company's business perspective on COVID-19 products when the disease becomes endemic.

Chief Executive Officer explained that The Company's operation is not initially tied to COVID-19 in any manner, but due to the situation with COVID-19, the Company has imported medical testing kits for sale, and opening a testing room for RT-PCR testing for COVID-19, which is adapted from cervical cancer (HPV) testing room. If COVID-19 becomes an endemic disease, it is expected that ATK testing kits will continue to be in demand, albeit at a lower level, while RT-PCR testing rooms will revert to their original purpose of cervical cancer (HPV) testing rooms, and products affected by COVID-19, such as blood-sucking insect trap products and blood banks, will see a better response. If COVID-19 becomes endemic, the company's executives are convinced that it will resume significant growth.

Since no shareholders had any additional questions or proposed matters for inclusion in this agenda, it was deemed that the Company had considered all the agendas as specified in the invitation letter for all agendas. The Chairman, therefore, adjourned the Meeting and thanked all of the shareholders who had taken the time to attend the Meeting today.

The Meeting was closed at 10:00 hrs.

Terdsak Rojsurakitti
_____ Chairman of the Board
(Asst Prof Dr. Terdsak Rojsurakitti)

_____ Company Secretary
(Ms. Yodjuta Kunjara na Ayudhya)